3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
1934
Neoplasms
1387
Carcinoma, Non-Small-Cell Lung
1328
Prostatic Neoplasms
1072
Multiple Myeloma
857
Leukemia, Myeloid, Acute
764
Neoplasm Metastasis
693
Colorectal Neoplasms
679
Melanoma
671
Lung Neoplasms
666
Lymphoma
656
Leukemia
592
Lymphoma, Non-Hodgkin
588
Leukemia, Lymphocytic, Chronic, B-Cell
529
Ovarian Neoplasms
522
Pancreatic Neoplasms
493
Precursor Cell Lymphoblastic Leukemia-Lymphoma
473
Recurrence
466
Myelodysplastic Syndromes
422
Lymphoma, Follicular
407
Head and Neck Neoplasms
402
Carcinoma, Renal Cell
377
Glioblastoma
376
Lymphoma, Large B-Cell, Diffuse
372
Brain Neoplasms
371
Hodgkin Disease
352
Carcinoma, Hepatocellular
325
Squamous Cell Carcinoma of Head and Neck
323
Lymphoma, Mantle-Cell
302
Sarcoma
281
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts